In June 2021, the Food and Drug Administration approved semaglutide under the brand name Wegovy for weight loss for persons without diabetes with overweight and a risk factor like high blood pressure, or high cholesterol and/or obesity
WARNING: If you are pregnant or breastfeeding, consult your physician before using this product
Procedures such as gastric bypass or sleeve gastrectomy can be performed safely after cholecystectomy
Continued use of Wegovy is generally safe for most patients, but it is important to adhere to the prescribed dosage and administration schedule
Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and weight management, while magnesium citrate serves as both a mineral supplement and osmotic laxative
Local Insight Metairie faces significant health challenges that mirror Louisiana's broader obesity crisis, with Jefferson Parish having higher than national average rates of diabetes and cardiovascular disease